Appointment of CHRISTOPHE MarÉchal AS chief financial officer
Liège, Belgium, 6 January 2017 - Mithra Pharmaceuticals (Euronext Brussels: MITRA), a company focused on women's health, today announces the appointment of Christophe Maréchal as Chief Financial Officer (CFO) with effect from 23 February 2017.
Mr Maréchal is currently Director, Group Treasury and Credit Risk Management, at Hamon Group (Euronext Brussels: HAMO), an engineering and contracting company. He has more than 20 years of financial experience in the international industrial, telecommunications, manufacturing and banking industries, including M&A, operational and financial strategy, and tactical initiatives to drive long-term business growth.
Before joining Hamon Group in 2006, Mr Maréchal held a number of positions at France Telecom Group in Paris, London and Brussels, including Deputy Group Treasurer. He holds a Masters in Business Administration from the University of Liège, Belgium, and studied econometrics at the Katholieke Universiteit Brabant, Tilburg, Netherlands.
Mr Maréchal takes over from Steven Peters, who will support him during the transition period.
Francois Fornieri, CEO of Mithra Pharmaceuticals, said: "Christophe is an excellent addition to our management team, with extensive financial and market experience across multiple fast-growing businessess. His skills and expertise will be particularly valuable as Mithra continues to expand its portfolio of innovative and valuable women's health products and to maximise their value through international collaborations and partnerships. I would also like to express our gratitude to Steven for his contribution to the business, including the successful IPO of Mithra in 2015, and wish him good luck in his future endeavours."
Christophe Maréchal said : "I am delighted to join Mithra at this key stage in its development, with a growing portfolio of established women's health products and a promising late-stage pipeline of innovative new approaches. Mithra has the potential to significantly expand its revenues and international presence in the next few years and I look forward to working with the excellent leadership team to help take the business to the next level of success."
For pictures of Christophe Maréchal, please click here on the following link:
For more information, please contact:
Chief Communication Officer
+32 4 349 28 22 / +32 475 86 41 75
François Fornieri, CEO
+32 4 349 28 22
Consilium Strategic Communications
Jonathan Birt, Sue Stuart, Hendrik Thys
+44 2 037 095 700
Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart, is a Euronext listed pharmaceutical company (MITRA) focused on Women's Health. Mithra's mission is to improve every stage of women's life with innovative and accessible pharmaceutical solutions. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical solutions in four therapeutic fields of women's health: fertility and contraception, menopause and osteoporosis, gynecological infections and female cancers.
Mithra has an approximate headcount of 141 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
To subscribe to Mithra's newsletter, visit investors.mithra.com
Source: Mithra Pharmaceuticals